LONDON--(BUSINESS WIRE)--Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial. The study, funded by the National Institute for Health and Care Research (NIHR), is evaluating 400mg progesterone Callavid® in patients diagnosed with luteal phase insufficiency, a condition where progesterone levels may be too low to support early pregnancy, increasing risk of infertility and recurrent miscarriage. C
Calla Lily Clinical Care Doses First Patients in Clinical Trial for Intravaginal Drug Delivery Platform for Threatened Miscarriage
